Talk:COVID-19 drug development - Wikipedia
2 people in discussion
Article ImagesMaterial from COVID-19 drug development was split to Bamlanivimab on 10 December 2020. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted so long as the latter page exists. Please leave this template in place to link the article histories and preserve this attribution. |
Multiple clinical trials are investigating the use of Interferon Lambda to treat COVID.[1][2][3]
Sabizabulin "halved the death rate among critically ill Covid patients who were receiving supplemental oxygen and were at high risk for serious lung disease and death"
New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claims https://www.nytimes.com/2022/04/11/health/covid-sabizabulin-veru.html
National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 53379371, Sabizabulin. Retrieved April 12, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Sabizabulin
Sabizabulin (VERU-111) for COVID-19 https://verupharma.com/pipeline/sabizabulin-for-covid-19/
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy https://www.globenewswire.com/news-release/2022/04/11/2419839/11676/en/Veru-s-Novel-COVID-19-Drug-Candidate-Reduces-Deaths-by-55-in-Hospitalized-Patients-in-Interim-Analysis-of-Phase-3-Study-Independent-Data-Monitoring-Committee-Halts-Study-Early-for-.html
2600:1000:B00F:64AC:D8E9:99AA:2866:936 (talk) 13:50, 12 April 2022 (UTC)Reply
- Thanks for posting this. We would not use the press releases as reliable sources for this information, so need to wait for peer reviewed articles or independent newspaper reports before including the supposed efficacy. In addition, this might be more suitable for this article - COVID-19 drug repurposing research - as the drug was in development already for cancer. Either way, I expect there will be more information published soon and if the press report is borne out then it should be included.
- Currently, one review lists the trial in a table , and it has a listing on ClinicalTrials.gov. |→ Spaully ~talk~ 14:14, 12 April 2022 (UTC)Reply
This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Specia = Special 2603:8000:D300:D0F:2098:B4E2:5069:2E94 (talk) 04:55, 28 July 2023 (UTC)Reply
- Not done: That appears to be a person's last name, located in a reference to this article which lists Megan Specia as an author. Tollens (talk) 05:13, 28 July 2023 (UTC)Reply